ABT-122 demonstrated acceptable tolerability and maintenance of efficacy at 36 weeks in patients with RA or PsA receiving background methotrexate.
Minimal disease activity provided a stable and valid assessment of clinical status over the course of 24 months in patients with psoriatic arthritis.
Sonographic enthesitis scoring instruments have been developed for spondyloarthritis, but only a few have been validated in psoriatic arthritis.
Researchers sought to estimate the occurrence of psoriatic arthritis in patients with psoriasis.
Widespread nonarthritic pain is linked to worse patient-reported and composite psoriatic arthritis activity measures.
Researchers analyzed the characteristics of patients with psoriatic arthritis with and without axial involvement.
Health-related quality of life was diminished in psoriatic arthritis at time of diagnosis compared with the general population.
Researchers sought to assess the reliability of the PGA for musculoskeletal and dermatologic manifestations in patients with psoriatic arthritis.
High-intensity interval training showed no clear effects on disease activity markers in patients with psoriatic arthritis.
Health-related quality of life was similar in patients with rheumatoid arthritis and psoriatic arthritis.
Male gender was associated with better biologic treatment effectiveness in psoriatic arthritis.
ABT-122 demonstrated efficacy and safety similar to adalimumab over 12 weeks in patients with psoriatic arthritis who had an inadequate response to methotrexate.
The FDA has approved updated labeling for Cosentyx that includes data demonstrating that the drug slows the progression of joint structural damage in patients with active psoriatic arthritis.
Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic CharacteristicsJune 20, 2018
It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.
In biologic-naive patients with psoriatic arthritis who are treated with apremilast, early onset of effect was observed across disease PsA manifestations.
The objective of this cross-sectional analysis was to evaluate the prevalence of osteoporosis and frequency of fractures in patients with psoriasis or psoriatic arthritis.
Researchers sought to compare baseline characteristics between patients with PsA who achieved and did not achieve minimal disease activity with biologic therapy.
The outcome measure may be considered a practical alternative to the Psoriasis Area and Severity Index for the measurement of psoriasis severity and response to therapy.
The CONTEST questionnaire includes the most discriminative questions from the three existing questionnaires.
Experts are still debating the utility of a unidimensional composite score compared with a multidimensional score for the assessment of disease activity in psoriatic arthritis.
Investigators sought to determine the rate of conversion of Quantiferon-TB Gold screening test in patients taking anti-TNF therapy.
Researchers sought to evaluate the prevalence rates of peripheral joint, enthesis, tendon, and bursa abnormalities by power Doppler ultrasound in patients with psoriatic arthritis and patients with psoriasis without clinical signs of arthritis.
The incidence of adverse cardiovascular events in patients with RA do not differ significantly compared with those with PsA or axSpA.
Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.
Researchers aimed to compare the disease burden of patients with psoriatic arthritis with low disease activity according to 2 definitions.
Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.
Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.
The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.
Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.
The results of the FUTURE 5 study show that secukinumab improved signs and symptoms and inhibited radiographic structural progression at 24 weeks in psoriatic arthritis.
Rheumatology Advisor Articles
- Efficacy of ABT-122 Maintained in Psoriatic Arthritis, Rheumatoid Arthritis at 36 Weeks
- Comorbid Fibromyalgia Influences Disease Activity, Quality of Life in Axial Spondyloarthritis
- Knee Load Associated With Increased Walking Pain in Osteoarthritis
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- CVD Prevention Measures Inadequate in Patients With Inflammatory Joint Diseases
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- Exploring the Clinical Implications of Cannabinoid Use in Rheumatoid Arthritis
- Diagnosing Lyme Disease in Children With Neuropsychiatric Illness
- Predicting Primary Nonresponse to Methotrexate in Rheumatoid Arthritis
- Prednisone, Prednisolone Does Not Adversely Affect Bone Mineral Density in RA
- Sulfasalazine Reduces Pneumocystis Pneumonia Risk in Rheumatoid Arthritis
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Response to Certolizumab Pegol at 12 Weeks Predicts Long-Term RA Outcomes
- Performance Phenotypes of Lumbar Spinal Stenosis and OA With Accelerometry Data
- Characteristics of Early-Onset SLE Distinguished From Mimicking Conditions